Liquidia (NASDAQ:LQDA) Now Covered by Analysts at Scotiabank

Scotiabank started coverage on shares of Liquidia (NASDAQ:LQDA) in a research report report published on Wednesday, Marketbeat Ratings reports. The firm issued a sector outperform rating and a $30.00 price target on the stock.

Several other research firms have also recently issued reports on LQDA. Bank of America cut their target price on Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. Lifesci Capital began coverage on shares of Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price objective for the company. Raymond James raised shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a report on Monday, August 19th. BTIG Research cut their target price on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, August 19th. Finally, HC Wainwright decreased their price target on shares of Liquidia from $32.00 to $29.00 and set a “buy” rating on the stock in a research note on Tuesday, August 20th. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $24.67.

Liquidia Price Performance

Shares of NASDAQ LQDA opened at $11.63 on Wednesday. The stock has a market cap of $888.69 million, a PE ratio of -7.46 and a beta of 0.22. Liquidia has a 1 year low of $5.71 and a 1 year high of $16.99. The firm has a fifty day moving average price of $10.42 and a 200-day moving average price of $11.97.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $3.66 million during the quarter, compared to the consensus estimate of $7.92 million. Liquidia had a negative return on equity of 183.57% and a negative net margin of 755.46%. On average, research analysts expect that Liquidia will post -1.69 EPS for the current year.

Insider Activity at Liquidia

In related news, Director Caligan Partners Lp acquired 150,000 shares of Liquidia stock in a transaction on Friday, August 30th. The shares were bought at an average cost of $9.51 per share, with a total value of $1,426,500.00. Following the completion of the purchase, the director now directly owns 6,994,997 shares of the company’s stock, valued at $66,522,421.47. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Caligan Partners Lp acquired 150,000 shares of the company’s stock in a transaction on Friday, August 30th. The stock was bought at an average cost of $9.51 per share, with a total value of $1,426,500.00. Following the completion of the purchase, the director now directly owns 6,994,997 shares of the company’s stock, valued at $66,522,421.47. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Russell Schundler sold 2,576 shares of the stock in a transaction on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $28,619.36. Following the completion of the sale, the general counsel now directly owns 486,048 shares in the company, valued at approximately $5,399,993.28. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,731 shares of company stock valued at $249,571. Insiders own 31.60% of the company’s stock.

Institutional Trading of Liquidia

Institutional investors have recently added to or reduced their stakes in the company. Patient Square Capital LP purchased a new stake in shares of Liquidia in the first quarter worth approximately $105,942,000. Vanguard Group Inc. increased its stake in Liquidia by 1.5% in the first quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company’s stock worth $42,587,000 after purchasing an additional 43,352 shares during the period. Farallon Capital Management LLC purchased a new stake in Liquidia in the first quarter worth $30,311,000. Whitefort Capital Management LP boosted its stake in shares of Liquidia by 45.8% during the first quarter. Whitefort Capital Management LP now owns 337,607 shares of the company’s stock valued at $4,980,000 after purchasing an additional 106,049 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in shares of Liquidia by 119.4% during the first quarter. BNP Paribas Financial Markets now owns 230,248 shares of the company’s stock valued at $3,396,000 after purchasing an additional 125,315 shares during the period. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).